Lenalidomide downregulates the cell survival factor, interferon regulatory factor‐4, providing a potential mechanistic link for predicting response
Open accessThe DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Abstract
Summary: Overexpression of the transcription factor interferon regulatory factor‐4 (IRF4), which is common in multiple myeloma (MM), is associated with poor prognosis. Patients with higher IRF4 expression have significantly poorer overall survival than those with low IRF4 expression. Lenalidomide is an IMiD® immunomodulatory compound that has both tumouricidal and immunomodulatory activity in MM. This study showed that lenalidomide downregulated IRF4 levels in MM cell lines and bone marrow samples within 8 h of drug exposure. This was associated with a decrease in MYC levels, as well as an initial G1 cell cycle arrest, decreased cell proliferation, and cell death by day 5 of treatment. In eight MM cell lines, high IRF4 levels correlated with increased lenalidomide sensitivity. The clinical significance of this observation was investigated in 154 patients with MM. Among MM patients with high levels of IRF4 expression, treatment with lenalidomide led to a significantly longer overall survival than other therapies in a retrospective analysis. These data confirm the central role of IRF4 in MM pathogenesis; indicate that this is an important mechanism by which lenalidomide exerts its antitumour effects; and may provide a mechanistic biomarker to predict response to lenalidomide.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
International uniform response criteria for multiple myeloma
Durie, B. G. M., Harousseau, J.-L., Miguel, J. S., Bladé, J., Barlogie, B., Anderson, K., Gertz, M., Dimopoulos, M., Westin, J., Sonneveld, P., et al. (2006) · Leukemia · doi:10.1038/sj.leu.2404284 · Cited by 2,632 · cited 1×
“Responses were assessed according the International Myeloma Working Group criteria (Durie et al, 2006).”
MethodSelf-citationLenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma
Dimopoulos, M., Spencer, A., Attal, M., Prince, H. M., Harousseau, J.-L., Dmoszynska, A., Miguel, J. S., Hellmann, A., Facon, T., Foà, R., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070594 · Cited by 1,450 · cited 1×
“It is highly active in combination with the corticosteroid dexamethasone in myeloma patients who have received at least one prior therapy (Dimopoulos et al, 2007, 2009, 2011; Weber et al, 2007).”
BackgroundLenalidomide plus Dexamethasone for Relapsed Multiple Myeloma in North America
Weber, D. M., Chen, C., Niesvizky, R., Wang, M., Belch, A., Stadtmauer, E. A., Siegel, D., Borrello, I., Rajkumar, S. V., Chanan-Khan, A. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070596 · Cited by 1,233 · cited 1×
“It is highly active in combination with the corticosteroid dexamethasone in myeloma patients who have received at least one prior therapy (Dimopoulos et al, 2007, 2009, 2011; Weber et al, 2007).”
BackgroundAnnunziata, C. M., Davis, R. E., Demchenko, Y., Bellamy, W., Gabrea, A., Zhan, F., Lenz, G., Hanamura, I., Wright, G., Xiao, W., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.07.004 · Cited by 952
Rajkumar, S. V., Jacobus, S., Callander, N. S., Fonseca, R., Vesole, D. H., Williams, M. E., Abonour, R., Siegel, D. S., Katz, M., & Greipp, P. R. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70284-0 · Cited by 933 · cited 1×
“…plus lenalidomide resulted in superior overall survival (OS) and reduced toxicity compared with high-dose dexamethasone plus lenalidomide (Rajkumar et al, 2010), indicating that dexamethasone adds toxicity and may limit some of the beneficial effects of lenalidomide while enhancing…”
BackgroundHideshima, T., Chauhan, D., Shima, Y., Raje, N., Davies, F. E., Tai, Y.-T., Treon, S. P., Lin, B., Schlossman, R. L., Richardson, P., et al. (2000) · Blood · doi:10.1182/blood.v96.9.2943 · Cited by 875
Richardson, P. G., Schlossman, R. L., Weller, E., Hideshima, T., Mitsiades, C., Davies, F., LeBlanc, R., Catley, L. P., Doss, D., Kelly, K., et al. (2002) · Blood · doi:10.1182/blood-2002-03-0996 · Cited by 804
IRF4 addiction in multiple myeloma
Shaffer, A. L., Emre, N. C. T., Lamy, L., Ngo, V. N., Wright, G., Xiao, W., Powell, J., Dave, S., Yu, X., Zhao, H., et al. (2008) · Nature · doi:10.1038/nature07064 · Cited by 730 · cited 18×
“In addition, IRF4 is often upregulated in a larger proportion of MM patients in coordination with upregulation of MYC (Shaffer et al, 2008).”
BackgroundMethodResultInfluentialRequirement for the Transcription Factor LSIRF/IRF4 for Mature B and T Lymphocyte Function
Mittrücker, H.-W., Matsuyama, T., Grossman, A., Kündig, T. M., Potter, J., Shahinian, A., Wakeham, A., Patterson, B., Ohashi, P. S., & Mak, T. W. (1997) · Science · doi:10.1126/science.275.5299.540 · Cited by 583 · cited 3×
“Interferon regulatory factor-4 is a transcription factor that is restricted in expression to the immune system and is an essential regulator at multiple stages of B-lymphoid development (Mittrücker et al, 1997; Acquaviva et al, 2008).”
BackgroundRichardson, P. G., Blood, E., Mitsiades, C. S., Jagannath, S., Zeldenrust, S. R., Alsina, M., Schlossman, R. L., Rajkumar, S. V., Desikan, K. R., Hideshima, T., et al. (2006) · Blood · doi:10.1182/blood-2006-04-015909 · Cited by 523 · cited 1×
“Similar to the modulation of IRF4 expression described here, previous correlative studies of phase 1 and 2 trials have shown a significant increase in sICAM, IL-2, IL-12, and c-interferon production with lenalidomide in patients with relapsed or refractory MM (Richardson et al, 2002, 2006).”
ResultDimopoulos, M. A., Chen, C., Spencer, A., Niesvizky, R., Attal, M., Stadtmauer, E. A., Petrucci, M. T., Yu, Z., Olesnyckyj, M., Zeldis, J. B., et al. (2009) · Leukemia · doi:10.1038/leu.2009.147 · Cited by 363 · cited 1×
“It is highly active in combination with the corticosteroid dexamethasone in myeloma patients who have received at least one prior therapy (Dimopoulos et al, 2007, 2009, 2011; Weber et al, 2007).”
BackgroundDeregulation of MUM1/IRF4 by chromosomal translocation in multiple myeloma
Iida, S., Rao, P. H., Butler, M., Corradini, P., Boccadoro, M., Klein, B., Chaganti, R. S. K., & Dalla-Favera, R. (1997) · Nature Genetics · doi:10.1038/ng1097-226 · Cited by 337 · cited 3×
“In MM cells, IRF4 is directly upregulated through the translocation between IGH@ and its locus (t4;16) in <10% of cases, with other MM cells demonstrating increases in NFjB that lead to IRF4 upregulation (Iida et al, 1997; Annunziata et al, 2007).”
BackgroundInfluentialRengarajan, J., Mowen, K. A., McBride, K. D., Smith, E. D., Singh, H., & Glimcher, L. H. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20011128 · Cited by 333 · cited 2×
“IRF4 expression can be modulated by a number of proteins, including NFjB; IL-4 and STAT-6; the ETS transcription factors PU-1 and SPIB; and perhaps even downstream of IBP, a small GTPase (Gupta et al, 1999; Rengarajan et al, 2002; Fanzo et al, 2006; Annunziata et al, 2007; Chen et al, 2008).”
BackgroundLenalidomide and Thalidomide: Mechanisms of Action—Similarities and Differences
Anderson, K. C. (2005) · Seminars in Hematology · doi:10.1053/j.seminhematol.2005.10.001 · Cited by 245
Verhelle, D., Corral, L. G., Wong, K., Mueller, J. H., Moutouh-de Parseval, L., Jensen-Pergakes, K., Schafer, P. H., Chen, R., Glezer, E., Ferguson, G. D., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-2317 · Cited by 234 · cited 1×
“It is highly active in combination with the corticosteroid dexamethasone in myeloma patients who have received at least one prior therapy (Dimopoulos et al, 2007, 2009, 2011; Weber et al, 2007).”
BackgroundSelf-citationRecurrent translocations involving the IRF4 oncogene locus in peripheral T-cell lymphomas
Feldman, A. L., Law, M., Remstein, E. D., Macon, W. R., Erickson, L. A., Grogg, K. L., Kurtin, P. J., & Dogan, A. (2009) · Leukemia · doi:10.1038/leu.2008.320 · Cited by 211 · cited 2×
“In mature B-cells, it plays an important role in the adaptive immune responses, modulates germinal centre differentiation, immunoglobulin class switch recombination, and plasma cell differentiation (Mittrücker et al, 1997; Feldman et al, 2009).”
BackgroundRel Induces Interferon Regulatory Factor 4 (IRF-4) Expression in Lymphocytes
Grumont, R. J., & Gerondakis, S. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.191.8.1281 · Cited by 198 · cited 1×
“IRF4 production is stimulated by mitogens that activate the nuclear factor kappa-light-chain-enhancer of activated B cells (NFjB) pathway, as well as IL-4 via STAT-6 (Gupta et al, 1999; Grumont & Gerondakis, 2000).”
BackgroundIRF4: Immunity. Malignancy! Therapy?
Shaffer, A. L., Emre, N. C. T., Romesser, P. B., & Staudt, L. M. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1845 · Cited by 189 · cited 1×
“Such considerations are important, as risk-adjusted therapy is becoming an important consideration when deciding on the most effective treatment regimens for MM patients (Richardson, 2005; Shaffer et al, 2009; Dimopoulos et al, 2011).”
BackgroundChen, Q., Yang, W., Gupta, S., Biswas, P., Smith, P., Bhagat, G., & Pernis, A. B. (2008) · Immunity · doi:10.1016/j.immuni.2008.10.011 · Cited by 186 · cited 1×
“IRF4 expression can be modulated by a number of proteins, including NFjB; IL-4 and STAT-6; the ETS transcription factors PU-1 and SPIB; and perhaps even downstream of IBP, a small GTPase (Gupta et al, 1999; Rengarajan et al, 2002; Fanzo et al, 2006; Annunziata et al, 2007; Chen et al, 2008).”
BackgroundZhan, F., Colla, S., Wu, X., Chen, B., Stewart, J. P., Kuehl, W. M., Barlogie, B., & Shaughnessy, J. D. (2007) · Blood · doi:10.1182/blood-2006-07-038703 · Cited by 176 · cited 1×
“The increase in CDKN1B levels is interesting in that low expression of CDKN1B has previously been associated with shortened survival in MM patients (Zhan et al, 2007).”
BackgroundMUM1/IRF4 expression as a frequent event in mature lymphoid malignancies
Tsuboi, K., Iida, S., Inagaki, H., Kato, M., Hayami, Y., Hanamura, I., Miura, K., Harada, S., Kikuchi, M., Komatsu, H., et al. (2000) · Leukemia · doi:10.1038/sj.leu.2401696 · Cited by 174
Escoubet-Lozach, L., Lin, I.-L., Jensen-Pergakes, K., Brady, H. A., Gandhi, A. K., Schafer, P. H., Muller, G. W., Worland, P. J., Chan, K. W. H., & Verhelle, D. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4898 · Cited by 172 · cited 1×
“We previously reported that lenalidomide causes cell cycle arrest in Burkitt lymphoma and MM cell lines by increasing CDKN1A expression, which was regulated at the transcriptional level through a mechanism independent of TP53 (Escoubet-Lozach et al, 2009).”
BackgroundSelf-citationK. Gandhi, A., Kang, J., Capone, L., Parton, A., Wu, L., H. Zhang, L., Mendy, D., Lopez-Girona, A., Tran, T., Sapinoso, L., et al. (2010) · Current Cancer Drug Targets · doi:10.2174/156800910791054239 · Cited by 169
Self-citationRichardson, P., Jagannath, S., Hussein, M., Berenson, J., Singhal, S., Irwin, D., Williams, S. F., Bensinger, W., Badros, A. Z., Vescio, R., et al. (2009) · Blood · doi:10.1182/blood-2008-12-196238 · Cited by 158 · cited 1×
“Such considerations are important, as risk-adjusted therapy is becoming an important consideration when deciding on the most effective treatment regimens for MM patients (Richardson, 2005; Shaffer et al, 2009; Dimopoulos et al, 2011).”
BackgroundHsu, A. K., Quach, H., Tai, T., Prince, H. M., Harrison, S. J., Trapani, J. A., Smyth, M. J., Neeson, P., & Ritchie, D. S. (2011) · Blood · doi:10.1182/blood-2010-04-278432 · Cited by 158 · cited 1×
“…superior overall survival (OS) and reduced toxicity compared with high-dose dexamethasone plus lenalidomide (Rajkumar et al, 2010), indicating that dexamethasone adds toxicity and may limit some of the beneficial effects of lenalidomide while enhancing others (Gandhi et al, 2010; Hsu et al, 2011).”
BackgroundLineage-Specific Modulation of Interleukin 4 Signaling by Interferon Regulatory Factor 4
Gupta, S., Jiang, M., Anthony, A., & Pernis, A. B. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.190.12.1837 · Cited by 130 · cited 2×
“IRF4 production is stimulated by mitogens that activate the nuclear factor kappa-light-chain-enhancer of activated B cells (NFjB) pathway, as well as IL-4 via STAT-6 (Gupta et al, 1999; Grumont & Gerondakis, 2000).”
BackgroundCharacterization of MYC Translocations in Multiple Myeloma Cell Lines
Dib, A., Gabrea, A., Glebov, O. K., Bergsagel, P. L., & Kuehl, W. M. (2008) · JNCI Monographs · doi:10.1093/jncimonographs/lgn011 · Cited by 126 · cited 1×
“MYC deregulation has been shown to be an important pathway for MM progression, and both IRF4 and MYC are important targets for the therapy of MM (Dib et al, 2008).”
BackgroundThalidomide and lenalidomide: Mechanism-based potential drug combinations
Vallet, S., Palumbo, A. P., Raje, N. S., Boccadoro, M., & Anderson, K. C. (2008) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190802005191 · Cited by 121
Valentinuzzi, M. E. (2010) · Series on bioengineering and biomedical engineering · doi:10.1142/9789814293648_0006 · Cited by 118 · cited 1×
“Interestingly, lenalidomide monotherapy has been shown to be an effective and well-tolerated therapy for patients in whom a steroid-sparing approach is recommended (Richardson et al, 2002, 2009; Baz et al, 2010).”
BackgroundOptimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement
Dimopoulos, M. A., Palumbo, A. P., Attal, M., Beksaç, M., Davies, F. E., Delforge, M., Einsele, H., Hájek, R., Harousseau, J., da Costa, F. L., et al. (2011) · Leukemia · doi:10.1038/leu.2011.3 · Cited by 118 · cited 2×
“It is highly active in combination with the corticosteroid dexamethasone in myeloma patients who have received at least one prior therapy (Dimopoulos et al, 2007, 2009, 2011; Weber et al, 2007).”
BackgroundSelf-citationInterleukin-6 promotes multiple myeloma cell growth via phosphorylation of retinoblastoma protein
Urashima, M., Ogata, A., Chauhan, D., Vídriales, M., Teoh, G., Hoshi, Y., Schlossman, R., DeCaprio, J. A., & Anderson, K. C. (1996) · Blood · doi:10.1182/blood.v88.6.2219.bloodjournal8862219 · Cited by 107 · cited 1×
“In MM cells, RB1 is predominantly expressed in its phosphorylated form, which is conducive to cell growth (Urashima et al,1996).”
BackgroundGandhi, A. K., Kang, J., Naziruddin, S., Parton, A., Schafer, P. H., & Stirling, D. (2006) · Leukemia Research · doi:10.1016/j.leukres.2006.01.010 · Cited by 95 · cited 1×
“328 ª 2011 Blackwell Publishing Ltd, British Journal of Haematology, 154, 325–336 et al, 2000; Gandhi et al, 2006; Verhelle et al, 2007).”
BackgroundSelf-citationLoss of IRF-4–binding protein leads to the spontaneous development of systemic autoimmunity
Fanzo, J. C., Yang, W., Jang, S. Y., Gupta, S., Chen, Q., Siddiq, A., Greenberg, & Pernis, A. B. (2006) · Journal of Clinical Investigation · doi:10.1172/jci24096 · Cited by 86 · cited 2×
“IRF4 expression can be modulated by a number of proteins, including NFjB; IL-4 and STAT-6; the ETS transcription factors PU-1 and SPIB; and perhaps even downstream of IBP, a small GTPase (Gupta et al, 1999; Rengarajan et al, 2002; Fanzo et al, 2006; Annunziata et al, 2007; Chen et al, 2008).”
BackgroundLenalidomide: a novel anticancer drug with multiple modalities
Galustian, C., & Dalgleish, A. G. (2008) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656560802627903 · Cited by 80 · cited 1×
“Lenalidomide is an orally active immunomodulatory and antiproliferative agent with significant activity in a range of haematological disorders, including myelodysplastic syndromes, non-Hodgkin lymphoma, and MM (Galustian & Dalgleish, 2009).”
BackgroundChang, C.-C., Lorek, J., Sabath, D. E., Li, Y., Chitambar, C. R., Logan, B. R., Kampalath, B., & Cleveland, R. P. (2002) · Blood · doi:10.1182/blood-2002-01-0104 · Cited by 64 · cited 1×
“Although expression of IRF4 has been associated with a more favourable clinical course in some lymphomas (Chang et al, 2002), it generally correlates with poor clinical outcome in haematological malignancies (Ito et al, 2002; Sundram et al, 2005; Naresh, 2007).”
BackgroundIRF-4 functions as a tumor suppressor in early B-cell development
Acquaviva, J., Chen, X., & Ren, R. (2008) · Blood · doi:10.1182/blood-2007-10-117838 · Cited by 60 · cited 3×
“Interferon regulatory factor-4 is a transcription factor that is restricted in expression to the immune system and is an essential regulator at multiple stages of B-lymphoid development (Mittrücker et al, 1997; Acquaviva et al, 2008).”
BackgroundExpression of MUM1/IRF4 mRNA as a prognostic marker in patients with multiple myeloma
Heintel, D., Zojer, N., Schreder, M., Strasser‐Weippl, K., Kainz, B., Vesely, M., Gisslinger, H., Drach, J. W., Gaiger, A., Jaeger, U., et al. (2007) · Leukemia · doi:10.1038/sj.leu.2404895 · Cited by 36 · cited 3×
“Among patients with MM, 3-year survival rates of 82Æ5% and 50Æ4% in patients with low and high IRF4 expression respectively, have been reported (Heintel et al, 2008).”
BackgroundResultSelf-citationIto, M., Iida, S., Inagaki, H., Tsuboi, K., Komatsu, H., Yamaguchi, M., Nakamura, N., Suzuki, R., Seto, M., Nakamura, S., et al. (2002) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.2002.tb01307.x · Cited by 34 · cited 2×
“Although expression of IRF4 has been associated with a more favourable clinical course in some lymphomas (Chang et al, 2002), it generally correlates with poor clinical outcome in haematological malignancies (Ito et al, 2002; Sundram et al, 2005; Naresh, 2007).”
BackgroundUranishi, M., Iida, S., Sanda, T., Ishida, T., Tajima, E., Ito, M., Komatsu, H., Inagaki, H., & Ueda, R. (2005) · Leukemia · doi:10.1038/sj.leu.2403833 · Cited by 34 · cited 1×
“Among the molecular signalling functions associated with IRF4 expression, its ability to modulate Fasmediated apoptosis via caspase 8 might have an important role in tumourigenesis in MM (Uranishi et al, 2005; Fanzo et al, 2006).”
BackgroundGualco, G., Weiss, L. M., Harrington, W. J., & Bacchi, C. E. (2009) · The American Journal of Surgical Pathology · doi:10.1097/pas.0b013e3181bb9a18 · Cited by 34 · cited 1×
“…in multiple myeloma (Acquaviva et al, 2008), IRF4 translocations have also been reported in some B-cell non-Hodgkin lymphomas, peripheral T-cell lymphoma, and B-cell chronic lymphocytic leukaemia (Tsuboi et al, 2000; Ito et al, 2002; Naresh, 2007; Feldman et al, 2009; Gualco et al, 2009).”
BackgroundA Role for Interferon Regulatory Factor 4 in Receptor Editing
Pathak, S., Ma, S., Trinh, L., & Lu, R. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.01946-07 · Cited by 33 · cited 1×
“In pre-B-cells, IRF4 activates immunoglobulin light chain rearrangements (Pathak et al, 2008).”
BackgroundSingle agent lenalidomide in newly diagnosed multiple myeloma: a retrospective analysis
Baz, R., Patel, M. P., Finley-Oliver, E., Lebovic, D. J., Hussein, M. A., Miller, K. C., Wood, M., Sher, T., Lee, K. P., & Chanan-Khan, A. A. (2010) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428191003721342 · Cited by 16
Management of the Relapsed/Refractory Myeloma Patient: Strategies Incorporating Lenalidomide
Richardson, P. G. G. (2005) · Seminars in Hematology · doi:10.1053/j.seminhematol.2005.10.004 · Cited by 16 · cited 1×
“Such considerations are important, as risk-adjusted therapy is becoming an important consideration when deciding on the most effective treatment regimens for MM patients (Richardson, 2005; Shaffer et al, 2009; Dimopoulos et al, 2011).”
Background
Research works printed but not linked: 3
- Li S., 2009, Lenalidomide shuts down the translational machinery in multiple myeloma cells resulting in down‐regulation of critical transcription factors such as C/EBPβ and IRF4 [abstract], Blood, 114
- 10.3324/haematol.10682 · doi:10.3324/haematol.10682
- 10.1111/j.0303-6987.2005.00298.x · doi:10.1111/j.0303-6987.2005.00298.x
Cited by
Buenrostro, J. D., Giresi, P. G., Zaba, L. C., Chang, H. Y., & Greenleaf, W. J. (2013) · Nature Methods · doi:10.1038/nmeth.2688 · Cited by 6,422
Lopez-Girona, A., Mendy, D., Ito, T., Miller, K., Gandhi, A. K., Kang, J., Karasawa, S., Carmel, G., Jackson, P., Abbasian, M., et al. (2012) · Leukemia · doi:10.1038/leu.2012.119 · Cited by 814
Self-citationCereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide
Zhu, Y. X., Braggio, E., Shi, C.-X., Bruins, L. A., Schmidt, J. E., Van Wier, S., Chang, X.-B., Bjorklund, C. C., Fonseca, R., Bergsagel, P. L., et al. (2011) · Blood · doi:10.1182/blood-2011-05-356063 · Cited by 607
Chamberlain, P. P., Lopez-Girona, A., Miller, K., Carmel, G., Pagarigan, B., Chie-Leon, B., Rychak, E., Corral, L. G., Ren, Y. J., Wang, M., et al. (2014) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2874 · Cited by 531
Self-citationExploiting Synthetic Lethality for the Therapy of ABC Diffuse Large B Cell Lymphoma
Yang, Y., Shaffer, A. L., Emre, N. C. T., Ceribelli, M., Zhang, M., Wright, G., Xiao, W., Powell, J., Platig, J., Kohlhammer, H., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.05.024 · Cited by 521
Metadata
- Authors
- Lopez‐Girona, A., Heintel, D., Zhang, L., Mendy, D., Gaidarova, S., Brady, H., Bartlett, J. B., Schafer, P. H., Schreder, M., Bolomsky, A., Hilgarth, B., Zojer, N., Gisslinger, H., Ludwig, H., Daniel, T., Jäger, U., & Chopra, R.
- Venue
- British Journal of Haematology
- Publisher
- Wiley
- Published
- 2011-06-24
- Volume
- 154
- Issue
- 3
- Pages
- 325-336
- ISSN
- 0007-1048 (ISSN-L)
- 1365-2141
- OpenAlex
- W1537559901
- Cited by
- 181
- References
- 43
- FWCI
- 9.81
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.